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2Abstract
Melanin concentrating hormone (MCH) is an important regulator of food intake, 
glucose metabolism and adiposity. However, the mechanisms mediating these actions 
remain largely unknown. We used pharmacological and genetic approaches to show that 
the SIRT1/FoxO1 signaling pathway in the hypothalamic arcuate nucleus (ARC) 
mediates MCH-induced feeding, adiposity and glucose intolerance. MCH reduces 
POMC neuronal activity and the SIRT1/FoxO1 pathway regulates the inhibitory effect 
of MCH on POMC expression. Remarkably, the metabolic actions of MCH are 
compromised in mice lacking SIRT1 specifically in POMC neurons. Of note, the 
actions of MCH are independent of AgRP neurons because inhibition of GABA-R in 
the ARC did not prevent the orexigenic action of MCH; and the hypophagic effect of 
MCH silencing was maintained after chemogenetic stimulation of AgRP neurons. 
Central SIRT1 is required for MCH-induced weight gain through its actions on the 
sympathetic nervous system. The central MCH knockdown causes hypophagia and 
weight loss in diet-induced obese wild type mice, however, these effects were abolished 
in mice over-expressing SIRT1 fed a high fat diet. These data reveal the neuronal basis 
for the effects of MCH on food intake, body weight and glucose metabolism and 
highlight the relevance of SIRT1/FoxO1 pathway in obesity. 
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3Abbreviations
MCH: Melanin concentrating hormone; MCHR1: MCH receptor; LHA: lateral 
hypothalamic area; SIRT1: sirtuin 1; POMC:  pro-opiomelanocortin; Agrp: Agouti 
related peptide; FoxO1: forkhead box O1; ARC: hypothalamic arcuate nucleus; 
αMSH: alpha melanocyte stimulating hormone; MC3R: melanocortin receptor 3; 
MC4R: melanocortin receptor 4: DIO: diet-induced obesity; WAT: white adipose 
tissue; GLP-1: glucagon-like peptide 1; SNS: sympathetic nervous system; PSNS: 
parasympathetic nervous system; CART: cocaine- and amphetamine-regulated 
transcript; TG: triglycerides; AMPK: AMP-activated protein kinase; ACC: acetyl-CoA 
carboxylase; FAS: fatty acid synthase.
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MCH is a 19-amino acid neuropeptide predominantly expressed in the LHA that plays a 
pivotal role in the regulation of energy homeostasis (1; 2). The central infusion of MCH 
induces feeding (3) and over-expression of MCH in transgenic mice leads to obesity (4). 
Conversely, pharmacological inhibition of MCHR1 reduces appetite, body weight and 
adiposity (5-7). In line with this, the lack of MCH causes hypophagia and leanness (8), 
attenuates leptin deficiency–induced obesity (9; 10), diet-induced obesity (DIO) (11), 
aging-associated increases in body weight and insulin resistance (12) and protects from 
hepatosteatosis (13). Independent of its actions on feeding and body weight, MCH 
induces insulin resistance (4; 14), and MCH-expressing neurons are stimulated by 
glucose and involved in the control of peripheral glucose homeostasis (15). In addition, 
MCH neurons are both necessary and sufficient for sensing the nutrient value of sucrose 
indicating that these neurons play a critical role in establishing nutrient preference (16). 
MCH also favors lipid storage in white adipose tissue (WAT) and liver through the 
sympathetic nervous system (SNS) and parasympathetic nervous system (PSNS), 
respectively (17).
MCH binds to MCHR1 (18), and MCHR1 deficient mice are lean, hypophagic and 
resistant to diet-induced obesity (19; 20). MCHR1 and MCH projections are widely 
distributed throughout the brain (21-26) suggesting that MCH is implicated in a large 
variety of functions. The complexity of the MCH system raises the possibility that 
multiple mechanisms underlie the biological actions of this neuropeptide. In line with 
this, MCH-induced food intake is blocked by different anorexigenic factors such as α-
MSH (27; 28) , GLP-1 (28) and neuropeptide Y antagonism (29). 
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5On the other hand, SIRT1 is a highly conserved NAD+-dependent deacetylase, which is 
activated in response to calorie restriction and acts as a cellular sensor to detect energy 
availability and regulate metabolism in a wide variety of tissues [for review see (30-
32)]. Hypothalamic SIRT1 controls energy balance (33; 34) and these actions are at 
least partially mediated by the melanocortin system (35; 36). The lack of SIRT1 in 
POMC neurons leads to increased weight gain (37), while its deficiency in AgRP 
neurons leads to a lean phenotype (36).  
Although the anabolic action of MCH was first shown nearly twenty years ago (3) and 
its physiological relevance is beyond any doubt, the neuronal circuits controlling this 
action remain largely unknown. We describe that MCH requires a 
SIRT1/FoxO1/POMC signaling pathway within the ARC to modulate feeding, 
adipocyte lipid metabolism and glucose metabolism.
Research design and methods
Animals and surgery
Eight-ten-week-old Sprague Dawley male rats, male C57/BL6 wild type (WT) and mice 
with moderate overexpression of SIRT1 (SIRT1 Tg) under the control of its own 
promoter, and Pomc-Cre:ROSA-tdTomato mice were housed in individual cages under 
conditions of controlled temperature (23°C) and illumination (12-hour light/12-hour 
dark cycle). Animals were allowed ad libitum access to water and standard laboratory 
chow or high fat diet (60% by energy, D12492, Research Diets, NJ, US). All 
experiments and procedures involved in this study were reviewed and approved by the 
Ethics Committee of the USC, the Institutional Ethics Committees for the Care and Use 
of Experimental Animals of the Universities of Lille and the University of Iowa Animal 
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animals. 
Patch-clamp recordings
Whole-cell patch-clamp recordings were performed in current-clamp mode as 
previously described (38) (see Supplemental information).
Intracerebroventricular infusions
ICV infusions in both rats and mice were conducted as described (39) (see 
Supplemental information).  
Stereotaxic microinjection of lentiviral expression vectors
 Lentiviral vectors expressing green fluorescent protein (GFP) and inhibiting SIRT1 
(shSIRT1),  FoxO1 (shFoxO1), MCHR1 (shMCHR1), POMC (shPOMC) (3,1X1006 
PFU/ml) (SIGMA-Aldrich) and GABA-R (shGABA-R) genes or scrambled sequences 
were injected bilaterally into the ARC (anterior to bregma (AP) −2.85 mm, lateral to the 
sagittal suture (L) ±0,3 mm, and ventral from the surface of the skull (V) -10,2 mm), 
with a microliter syringe (17; 40-42). The viral particles (1 l, 3,1X1006 PFU/ml) were 
infused over 5 minutes and the injector kept in place for an additional 5 minutes. GFP 
fluorescence, visualized under the microscope, was used as a marker of effective 
transduction of the lentivirus at the injection site. Dissection of the ARC was performed 
by micropunches under the microscope, as previously reported (43; 44). The specificity 
of the ARC dissection was confirmed by analysing the mRNA of specific markers, 
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VMH. To inhibit the expression of SIRT1 specifically in POMC neurons, we injected 
into the ARC AAV8-hSyn-DIO-GFP or AAV8-hSyn-shSIRT1-DIO-GFP of mice 
expressing Cre I POMC neurons. POMC-IRES-Cre, mice were anesthetized and placed 
in a stereotaxic frame (Kopf Instruments). Specific infection of AAV in POMC neurons 
was evaluated by immunohistochemistry. In all experimental settings body weight and 
food intake were recorded until 2-3 weeks after the surgery, and then, we perform the 
acute or chronic MCH treatments.
Western blot analysis and Real time PCR
Western blot and Real Time PCR were performed as described previously (17) (see 
Supplemental information). 
Statistical analysis and data presentation
Data are expressed as mean ± SEM. Protein data were expressed in relation (%) to 
control (vehicle or GFP-treated) rats/mice. SNA was expressed as a percent change 
from baseline. Statistical significance was determined by t-Student when two groups 
were compared or One-Way ANOVA and post hoc one-tailed Bonferroni test when 
more than two groups were compared. A p < 0.05 was considered significant.
Data and Resource Availability
The data that support the findings of this study are available from the corresponding 
author upon request.
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Central MCH stimulates FoxO1 and inhibits POMC protein levels via MCH-R in 
the ARC
As expected, an acute icv bolus of MCH increased feeding after 2h of injection in 
satiated Sprague Dawley rats (Figure 1A). Icv MCH-treated rats showed unchanged 
levels of hypothalamic pAMPK, p-mTOR and enzymes involved in fatty acid 
metabolism (Supplementary Figure 1A). However, MCH diminished acetyl–p53 levels, 
a surrogate marker of SIRT1 activity, and therefore decreased acetyl-FoxO1 levels, 
while raising FoxO1 protein levels in the hypothalamus (Figure 1B). Additionally, we 
found that central MCH significantly decreased POMC protein levels whereas no 
changes were observed in NPY, AgRP or CART (Figure 1C and Supplementary Figure 
1B). Remarkably these molecular changes induced by MCH are observed also at the 
mRNA level (Supplementary Figures 2A-2C). Moreover, our results show the 
specificity of MCH-induced changes in FoxO1 and SIRT1 protein levels in the ARC, 
because those effects were not found in other hypothalamic areas such as the VMH or 
the lateral hypothalamic area (Supplementary Figures 2D-2G). Of note, the specificity 
of the isolation of hypothalamic nuclei was corroborated by measuring POMC and SF1 
in the ARC and in the VMH (Supplementary Figures 2H-2I).
We combined ARC microinjection of vehicle or MCH with fluorescein-isothio-cyanate 
(FITC) that allowed us to control the diffusion of the treatment within the hypothalamus 
(Figure 1D). Consistent with bulk brain delivery of MCH, explicit targeting of MCH to 
the ARC stimulated food intake after 2h (Figure 1E), decreased acetyl-p53, acetyl-
FoxO1 and POMC while increasing FoxO1 protein levels within the ARC (Figure 1F). 
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MCH, we used lentivirus encoding a shRNA that silence MCHR1. Two weeks later, 
infection efficiency was assessed by the expression of GFP in the ARC (Figure 1G) and 
by the decreased protein levels of MCHR1 in the ARC (Figure 1H). Inhibition of ARC 
MCHR1 blunted the orexigenic effect of icv MCH (Figure 1I), and blocked MCH 
effects on FoxO1 and POMC protein levels in the ARC (Figure 1J). These results 
indicate that MCH requires the MCHR1 in the ARC to induce feeding and to regulate 
FoxO1 and POMC in this hypothalamic nucleus.
MCH reduces the activity of POMC neurons
By using FACS sorting and single-cell RNA sequencing of 163 POMC eGFP neurons, 
we found that 19% of POMC neurons express MCH receptor (MCH-R1), 45% of 
POMC neurons express SIRT1 and 84% of POMC neurons express FoxO1 (GEO 
Database repository: GEO Accession: GSE92707) (Figure 2A). Since electrical activity 
of ARC POMC neurons changes across the hunger-satiety cycle and selective sustained 
opto- or chemogenetic stimulation of these cells promote satiety (45), we performed 
whole-cell current-clamp recordings from fluorescent labeled cells in acute brain slices 
from Pomc-Cre:ROSA-tdTomato mice (Figure 2B) to ask whether MCH-induced 
hyperphagia is also paralleled by decreased electrical activity of anorexigenic ARC 
POMC neurons. We found that bath application of 1 µM MCH (46) reversibly reduced 
the spontaneous firing rate of 50% of ARC POMC neurons (6 out of 12 cells from 4 
mice) by 58.92±11.39% (n=6 cells from 4 mice) (Figures 2C and 2D), an effect that was 
accompanied by a membrane hyperpolarization of 6.83±0.65 mV (n=6 cells from 4 
mice) (Figures 2C and 2D). MCH had no effect on the 6 other cells tested (data not 
shown). Furthermore, the MCH-induced inhibitory effect on POMC neuronal firing 
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persisted in loose patch-clamp configuration (in 2 of 2 cells from 2 mice) (Figure 2E 
and 2F), indicating that it was not a consequence of dilution of the intracellular 
compartment by whole-cell dialysis. These results show that MCH inhibits the activity 
of ARC POMC neurons, an effect which together with the aforementioned MCH-
induced downregulation of POMC gene expression in the ARC converge towards an 
inhibition of the anorexigenic POMC signaling.
Central MCH requires POMC but not AgRP to stimulate feeding
Since MCH decreases POMC levels and POMC activity, we hypothesized that MCH-
antisense oligonucleotides (ASO), which are known to suppress feeding and to decrease 
MCH protein levels (data not shown), might require an up-regulation of POMC to exert 
their anorexigenic action. Thus, we next injected into the ARC a lentivirus encoding 
shRNA to silence POMC (Figure 3A) previous to the icv administration of MCH-ASO 
and found that the hypophagic action of MCH-ASO was blunted (Figure 3B). To rule 
out the potential role of AgRP neurons in the actions of MCH, we performed two 
additional studies. First, since AgRP neurons modulate POMC activity through the 
release of GABA, we silenced GABA-R in the ARC of rats to test the possible 
regulation of AgRP neurons over POMC neuronal activity (Figure3C). The knockdown 
of ARC GABA-R did not alter MCH-induced hyperphagia (Figure 3D). Second, using 
DREADDs technology, we stimulated AgRP neurons in mice and found a clear 
stimulation of feeding, but the chemogenetic stimulation of AgRP neurons did not 
prevent the hypophagic action of the MCH-ASO (Figures 3E-3F). Thus, POMC but not 
AgRP is required for the orexigenic action of MCH.
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Central MCH requires the interaction between SIRT1 and FoxO1 to stimulate 
feeding
We next assessed whether pharmacological or genetic blockade of SIRT1 interfere with 
the orexigenic action of MCH. Icv Ex527, a selective SIRT1 inhibitor, administered 20 
min before icv MCH blunted the orexigenic action of MCH (Supplementary Figure 3A). 
Genetically inhibiting SIRT1 expression in the ARC via a lentivirus encoding a shRNA 
that silences SIRT1 (Figure 4A) blunted the orexigenic effect of icv MCH (Figure 4B), 
and blocked MCH-induced changes in FoxO1 and POMC protein levels in the ARC 
(Figure 4C). Of note, the titer and volume of lentiviruses encoding shSIRT1 used for 
these manipulations did not cause alterations in physiological body weight or food 
intake (Supplementary Figures 3B-3C). To evaluate the role of FoxO1 as the 
downstream mediator of SIRT1-dependent MCH orexigenic action, we administered 
into the ARC a lentivirus encoding a shRNA that silence FoxO1 (Figure 4D). Inhibition 
of ARC FoxO1 partially blocked the orexigenic effect of icv MCH (Figure 4E) and 
reversed the effects of MCH on POMC protein levels in the ARC (Figure 4F). 
ARC SIRT1 and FoxO1 are necessary for central MCH to promote adipocyte lipid 
storage and glucose intolerance
In order to study the role of SIRT1/FoxO1 pathway in central actions of MCH on 
adipocyte metabolism and glucose metabolism, we administered into the ARC a 
lentivirus encoding a shRNA SIRT1 together with GFP or adenovirus expressing GFP 
scrambled shRNA (control). Two weeks later, rats in each group received icv MCH or 
vehicle (saline) for one week. While chronic central infusion of MCH significantly 
induced weight gain and food intake, these effects were abolished in rats in which 
SIRT1 was silenced in the ARC (Figures 5A and 5B). Consistent with the increased 
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weight gain and previous report (17), MCH decreased WAT protein levels of pHSL and 
pJNK and increased CIDEA (Figure 5C). ARC SIRT1 silencing abolished these effects 
evoked by MCH in WAT (Figure 5C). In order to test if the actions of central MCH on 
WAT were mediated by thermogenesis or browning of WAT, we performed an 
immunohistochemistry of UCP-1 in WAT and BAT. Consistent with the previous study 
(17) MCH did not affect UCP1 levels  (Supplementary Figure 4). Since MCH also 
impairs glucose tolerance (4; 14), we next sought to investigate if ARC SIRT1 is 
involved in the effects of central MCH on glucose metabolism. Indeed, we found that 
the chronic central infusion of MCH caused glucose intolerance, but this action was 
blunted in rats that have SIRT1 genetically inhibited in the ARC (Figures 5D-5E). In 
order to assess if hypothalamic SIRT1 was also an essential mediator of the hepatic 
actions of MCH, we measured the hepatic TG content. In agreement with previous 
reports (13; 17) the central treatment with MCH augmented the amount of TG in the 
liver, and this effect was still persistent when ARC SIRT1 was down-regulated (Figure 
5F), indicating that SIRT1 does not mediate the central actions of MCH on hepatic lipid 
metabolism.
Next, we evaluated the role of the transcription factor FoxO1 as the downstream 
mediator of SIRT1-dependent MCH action on adipocyte metabolism and glucose 
intolerance, following a similar setting than the aforementioned for SIRT1. As 
expected, chronic central infusion of MCH induced significant weight gain (Figure 6A), 
hyperphagia (Figure 6B), decreased WAT pHSL and pJNK levels and increased WAT 
CIDEA (Figure 6C) and caused glucose intolerance (Figures 6D and 6E). Notably, all 
these MCH-induced effects were blunted in rats where FoxO1 was down-regulated in 
the ARC (Figures 6A-6E) independently of BAT thermogenesis or browning of WAT 
(Supplementary Figure 4).
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Inhibition of SIRT1 in POMC neurons compromises the MCH-induced feeding, 
body weight gain and adiposity
Since inhibition of SIRT1 in the ARC impairs the anabolic actions of MCH and MCH 
inhibits POMC neuronal activity, we hypothesized that specific inhibition of SIRT1 in 
POMC neurons could impair MCH function. To test this, we silenced SIRT1 
specifically in POMC neurons by injecting AAV8-hSyn-shSIRT1-DIO-GFP into the 
MBH of POMC-IRES-Cre mice. Our results showed the specificity of the infection 
because GFP staining was restricted to POMC neurons (Figure 7A). Three weeks after 
transfection, mini osmotic pumps were implanted in mice to deliver icv MCH or vehicle 
(saline) for one week. Chronic central infusion of MCH induced significant reduction of 
MBH acetyl-p53 levels (Figure 7B), weight gain (Figure 7C), hyperphagia (Figure 7D) 
and adiposity (Figure 7E). Notably, all these MCH-induced effects were blunted after 
inhibition of SIRT1 in POMC neurons (Figures 7B-7E). Therefore, these data suggest 
that SIRT1 specifically in POMC neurons mediates the anabolic actions of MCH. In 
addition, as we pointed in previous experiments, the anabolic role of MCH was 
independent of the browning of WAT since UCP1 immunostaining was unchanged in 
all the studied groups (Figures 7F-7H). 
SIRT1 mediates MCH-induced weight gain through the SNS
We previously demonstrated a key role of the SNS inhibition in central MCH-induced 
weight gain and adiposity (17). Therefore, we hypothesized that down-regulation of 
SIRT1 in the ARC modulate the efferent SNS subserving WAT. For this, we tested the 
effect of icv MCH on WAT SNA in absence or presence of EX-527, a SIRT1 
antagonist, administered icv. We found that: a) icv Ex527 (10ug/rat) stimulated WAT 
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SNA, b) icv MCH decreased WAT SNA, and c) a dose of icv EX527 that does not 
change WAT SNA per se was able to suppress the MCH-induced effect on WAT SNA 
(Figure 7I).
Genetic inhibition of central MCH decreases feeding and body weight in wild type 
but not in SIRT1 transgenic mice
Central injection of MCH-ASO at different doses (1, 2 and 4 nmol/mouse) decreased 
food intake and body weight in mice fed a chow diet (Figures 8A-8B). Next, we 
challenged WT mice and mice over-expressing SIRT1 with 60% high fat diet (HFD) for 
12 weeks. In WT mice fed a HFD, central administration of MCH-ASO caused a 
significant decrease in food intake and body weight (Figures 8C-8D), associated with a 
decrease in hypothalamic mediobasal FoxO1 levels (Figure 8E). However, central 
MCH-ASO injection to obese SIRT1 transgenic (Tg) mice failed to alter feeding 
behavior, body weight or hypothalamic FoxO1 levels after 24 hours (Figures 8F-8H). 
The injection of MCH-ASO decreased MCH protein levels in both WT and SIRT1 Tg 
mice after 24 hours (Supplementary Figures 5A-5B). 
Discussion
Here, we describe for the first time that MCH inhibit the electrical activity of POMC 
neurons and that SIRT1/FoxO1 mediate the MCH control of food intake, adipocyte lipid 
storage and glucose metabolism. The central melanocortin system interacts with SIRT1 
to modulate energy homeostasis and insulin sensitivity. Pharmacological or genetic 
inhibition of hypothalamic SIRT1 decrease food intake and weight gain and central 
administration of a specific melanocortin antagonist, SHU9119, reversed the anorectic 
Page 15 of 56
For Peer Review Only
Diabetes
15
effect of hypothalamic SIRT1 inhibition (35). Mice lacking SIRT1 in POMC neurons 
were more prone to DIO (37) and selective lack of SIRT1 in hypothalamic AgRP 
neurons decrease food intake, fat mass and body weight (36). We therefore 
hypothesized that hypothalamic SIRT1 might govern the metabolic actions of MCH. 
We focused our attention on the ARC based on the evidence identifying this 
hypothalamic area as the site where MCH acts to increase food intake and adipocyte 
lipid deposition (17). Mechanistic studies using pharmacological approach and viral 
vectors show that down-regulation of SIRT1 in the ARC blunts MCH-induced feeding. 
Accordingly, genetic silencing of SIRT1 in the ARC blunted adipocyte lipid storage and 
glucose intolerance caused by chronic central infusion of MCH. Although central MCH 
favors hepatic lipid deposition (13; 17), this action occurs in the LHA (17), but 
remained unaltered after inhibition of SIRT1 in the ARC, indicating the specificity of 
the MCH-SIRT1 pathway. Therefore, this data indicates that SIRT1 is as a mediator of 
the anabolic effects of MCH. Furthermore, the role of SIRT1 as a mediator of MCH is 
consistent with other reports suggesting that hypothalamic SIRT1 mediates the 
orexigenic action of ghrelin (36; 47). 
The SNS connects hypothalamic centers with the WAT, and we previously 
demonstrated that central MCH control adiposity through the SNS (17). Furthermore, 
hypothalamic SIRT1 modulates WAT SNA (37). Our findings show that whereas icv 
MCH decreased WAT SNA, central blockade of SIRT1 blunted this effect. In line with 
this, the actions of ARC SIRT1 as a modulator of MCH-induced adiposity could be 
controlled by the administration of a β-adrenoreceptor antagonist, indicating that WAT 
SNA is a downstream effector of SIRT1. Overall, these results indicate that 
hypothalamic SIRT1 requires the SNS to modulate the actions of MCH on body fat 
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mass. Thus, the central MCH/SIRT1 pathway represents a new neuronal circuit of the 
brain-WAT axis. The increased SIRT1 activity following MCH administration may at first 
seem counterintuitive, but there are several reports that studied the role of SIRT1 in the 
hypothalamus and the results are somehow controversial. While deletion of SIRT1 in 
POMC neurons causes a higher sensitivity to develop obesity when mice are fed a high fat diet 
(Ramadori G et al, Cell Metabolism 2010), we and others reported that ghrelin, a metabolic 
hormone, which similarly to MCH stimulates feeding and adiposity, and also inhibits the SNA 
in the WAT, requires hypothalamic SIRT1 to exert its effects (36; 47). Similarly, previous 
experimental evidence has shown that pharmacological inhibition of SIRT1 at the central level 
inhibits ghrelin-induced food intake and body weight through the regulation of the FOXO1 and 
the melanocortin system, including increased levels of acetyl-Foxo1 and POMC expression (35; 
36; 48). Thus, further studies are necessary to clarify the role of hypothalamic SIRT1. 
Importantly, our studies have identified FoxO1 as critical mechanism within the ARC 
by which the MCH-SIRT1 pathway controls food intake, adipocyte metabolism and 
glucose intolerance. Among the large list of molecules that are directly regulated by 
SIRT1, FoxO1 emerged as a potential candidate because of its interaction with the 
hypothalamic melanocortin system (49) and in mediating the metabolic effects of 
central SIRT1 (35). MCH administered icv or directly into the ARC upregulated 
hypothalamic protein levels of FoxO1, whereas genetic inhibition of ARC SIRT1 
abolished this effect. Similarly, to the results obtained with SIRT1, down-regulation of 
FoxO1 in the ARC blunted MCH-induced feeding, adipocyte lipid storage and glucose 
intolerance. 
To gain insights in the pathophysiological relevance of MCH/SIRT1/FoxO1 pathway in 
obesity, we injected MCH-ASO centrally, which decreased both food intake and weight 
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gain in wild type mice fed a chow diet or HFD. Icv MCH-ASO decreased hypothalamic 
levels of FoxO1 in wild type mice fed a HFD. However, central MCH-ASO failed to 
modify food intake or body weight in mice over-expressing SIRT1. This lack of effect 
was associated with inability of MCH-ASO to inhibit hypothalamic FoxO1. Finally, the 
interaction between the MCH system and SIRT1/FoxO1 appears to occur in POMC 
neurons. This is demonstrated because when we disrupt GABA signaling into the ARC 
neurons, which is the neurotransmitter in charge of the neural communication between 
AgRP and POMC neurons, central MCH is still able to stimulate feeding. Indeed, 
POMC neurons receive also inhibitory inputs from outside the ARC (40), but this 
results together with the fact that MCH-ASO maintained their hypophagic action after 
the chemogenetic stimulation of AgRP neurons, suggests that AgRP neurons fail to 
significantly influence MCH-mediated feeding. Moreover, our functional data showed 
that MCH dramatically inhibits spontaneous neuronal activity in a significant subset of 
POMC neurons. Indeed, we obtained certain variability in the response of these 
neurons, which was expected due to the high heterogeneity of POMC neurons based on 
their molecular taxonomy, neurotransmitter and receptor expression (50). Lastly, our 
hypothesis was countersigned/confirmed by the fact that the virogenetic deletion of 
SIRT1 specifically in POMC neurons blunted the actions of MCH. We found that in 
mice lacking SIRT1 in POMC neurons, MCH is less effective in inducing weight gain, 
feeding and adiposity compared to mice with intact SIRT1 expression in those neurons. 
The incomplete blockade of MCH actions in our animal model might be explained by 
the fact that the adenoviral vector did not infect all MCH-R-expressing POMC neurons, 
and that some of the infected POMC neurons likely did not express MCH-R. This is in 
concordance with the aforementioned heterogeneity of POMC neurons. Overall, our 
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findings conclusively suggest the key involvement of these neurons in MCH-mediated 
effects in the ARC.  
    
In summary, our data highlight the relevance of the MCH system as a drug target and 
provide new conceptual framework on the mechanisms by which MCH modulates food 
intake, adipocyte lipid storage and glucose intolerance via a SIRT1/FoxO1 in the ARC. 
This mechanism requires POMC but not AgRP neurons and is essential for the activity 
of MCH inhibitors in obesity.  
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Figure legends
Figure 1. Central MCH stimulates hypothalamic FoxO1 levels and down-regulates 
POMC protein levels through MCH-R in the ARC. Central effects of icv MCH 
administration (20µg/rat) on (A) food intake, (B) hypothalamic protein levels of acetyl-
p53, FoxO1, acetyl-FoxO1 and (C) hypothalamic protein levels of AgRP and POMC in 
rats after 2 hours. (D) Fluorescein-isothiocyanate (FITC) staining in the hypothalamic 
ARC. (E) Food intake and (F) ARC protein levels of acetyl-p53, FoxO1, acetyl-FoxO1 
and POMC in rats 2 hours after injection of MCH directly in the ARC. (G) GFP 
expression in the hypothalamic ARC after stereotaxic injection of shMCHR1 lentivirus. 
(H) Protein levels of MCH-R in the ARC of rats stereotaxically injected with scrambled 
or shMCHR1 lentiviruses. (I) Effect of icv MCH on food intake in rats stereotaxically 
injected with scrambled or shMCHR1 lentiviruses into the ARC. (J) Protein levels of 
FoxO1 and POMC in the hypothalamic ARC of rats stereotaxically injected with 
scrambled or shMCHR1 lentiviruses in the ARC and icv MCH. β-actin was used to 
normalize protein levels. Dividing lines indicate spliced bands from the same gel. 
Values are mean ± SEM of 7–10 animals per group. 
Figure 2. MCH inhibits the activity of POMC neurons in the ARC. (A) FACS 
sorting and single-cell RNA sequencing of POMC-eGFP neurons showing MCH-R, 
SIRT1 and FoxO1 expression (GEO Database repository: GEO Accession: GSE92707)
(B) Left: A spontaneously fluorescent ARC POMC neuron (arrow) from a Pomc-
Cre:ROSA-tdTomato mouse was identified for patch-clamp recording. Right: Infrared 
differential interference contrast (IR-DIC) of the same image showing a patched pipette 
(dotted lines) placed on the cell membrane of the identified POMC neuron (arrow). 
Scale bars: 50 µm. (C) Whole-cell current-clamp recording showing that MCH 
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reversibly decreased the spontaneous firing activity of the POMC neuron patched in 
(B). Note that the inhibitory effect was accompanied by a membrane hyperpolarization. 
Denoted regions of the recording are shown underneath with an expanded time scale. 
(D) Average membrane potential of ARC POMC neurons in control conditions and in 
the presence of MCH (***p<0.001, paired t test, n = 6 cells from 4 mice). (E) Average 
firing rate of ARC POMC neurons in control conditions and in the presence of MCH 
(*p<0.05, paired t test, n = 6 cells from 4 mice).  (F) Trace showing that MCH reduced 
the spontaneous firing activity of another ARC POMC neuron recorded in loose patch 
configuration. Pooled data are shown as mean ± SEM. *P≤0.05, **P≤0.01; and 
***P≤0.001 vs controls. 
 
Figure 3. Central MCH requires POMC but not AgRP to stimulate feeding. (A) 
POMC protein levels in the ARC and (B) effect of icv MCH-ASO on food intake in rats 
stereotaxically injected with scrambled or shPOMC lentiviruses in the ARC. (C) 
GABA-R protein levels in the ARC and (D) effect of icv MCH on food intake in rats 
stereotaxically injected with scrambled or shGABA-R lentiviruses in the ARC. (E) 
mCherry expression in the hypothalamic ARC after stereotaxic injection of hSYN-DIO-
Hm3D(Gq)-mCherry AVV. (F) Effect of icv MCH-ASO on food intake in AgRP-CRE 
mice stereotaxically injected with hSYN-DIO-Hm3D(Gq)-mCherry AVV in the ARC. 
β-actin was used to normalize protein levels. Dividing lines indicate spliced bands from 
the same gel. Values are mean ± SEM of 8–10 animals per group. *P≤0.05, **P≤0.01; 
and ***P≤0.001 vs controls. 
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Figure 4. Central MCH requires SIRT1 and FoxO1 in the hypothalamic ARC to 
stimulate feeding. (A) SIRT1 protein levels in the ARC, (B) effect of icv MCH on food 
intake, and (C) protein levels of FoxO1 and POMC in the hypothalamic ARC of rats 
stereotaxically injected with scrambled or shSIRT1 lentiviruses in the ARC and icv 
MCH. (D) FoxO1 protein levels in the ARC, (E) effect of icv MCH on food intake in 
rats, and (F) protein levels of POMC in the hypothalamic ARC of rats stereotaxically 
injected with scrambled or shFoxO1 lentiviruses in the ARC and icv MCH. β-actin was 
used to normalize protein levels. Dividing lines indicate spliced bands from the same 
gel. Values are mean ± SEM of 8–10 animals per group. *P≤0.05, **P≤0.01; and 
***P≤0.001 vs controls. 
Figure 5. SIRT1 in the ARC is essential for MCH-induced food intake, WAT lipid 
storage and glucose intolerance. (A) Body weight change, (B) cumulative food intake, 
(C) WAT protein levels of pHSL, pJNK and CIDEA, (D) glucose tolerance test, (E) 
area under the curve, and (F) hepatic triglyceride content in rats that received shSIRT1 
or GFP scrambled lentiviruses in the ARC followed by chronic icv MCH (10µg/day/rat) 
for 1 week. β-actin was used as loading control. Dividing lines indicate spliced bands 
from the same gel. Values are mean ± SEM of 7–10 animals per group. *P≤0.05, 
**P≤0.01; and ***P≤0.001 vs controls. 
Figure 6. FoxO1 in the ARC is essential for MCH-induced food intake, WAT lipid 
storage and glucose intolerance. (A) Body weight change, (B) cumulative food intake, 
(C) WAT protein levels of pHSL, pJNK and CIDEA, (D) glucose tolerance test, and (E) 
area under the curve in rats that microinjected with shFoxO1 or GFP scrambled 
lentiviruses into the ARC before icv MCH (10µg/day/rat) for 1 week. β-actin was used 
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as loading control. Dividing lines indicate spliced bands from the same gel. Values are 
mean ± SEM of 7–10 animals per group. *P≤0.05, **P≤0.01; and ***P≤0.001 vs 
controls. 
Figure 7. SIRT1 in the POMC neurons regulates MCH-induced food intake, body 
weight and WAT lipid storage. Representative immunofluorescence showing GFP and 
POMC colocalization (A). MBH protein levels of acetyl-p53 and p53 (B). Body weight 
change (C); cumulative food intake (D); fat mass (E); representative pictures of WAT 
histology (hematoxylin-eosin) (F), WAT protein levels of UCP1 (G); BAT mass (H).  
Effect of pre-treatment with vehicle versus SIRT1 antagonist Ex-527 (5 µg/rat and 
10µg/rat) on WAT SNA response evoked by icv MCH (10µg/rat) in rats (I); β-actin was 
used to normalize protein levels. Dividing lines indicate spliced bands from the same 
gel. Values are mean ± SEM of 6–10 animals per group.  *P < 0.05; **P < 0.01 and 
***P < 0.001 vs controls. 
Figure 8. Over-expression of SIRT1 blunts MCH-ASO-induced hypophagia. Effect 
of icv MCH-ASO (1, 2 and 4 nmol/mouse) on (A) food intake and (B) body weight 
change in wild type mice fed a chow diet. Effect of icv MCH-ASO (1, 2 and 4 
nmol/mouse) on (C) food intake, (D) body weight change, and (E) protein levels of 
FoxO1 in the MBH of wild type mice fed a high fat diet (HFD). Effect of icv ASO-
MCH (2 nmol/mouse) on (F) food intake, (G) body weight change, and (H) protein 
levels of FoxO1 in the MBH of SIRT1 transgenic (Tg) mice fed a HFD. β-actin was 
used to normalize protein levels. Dividing lines indicate spliced bands from the same 
gel. Values are mean ± SEM of 6–10 animals per group. *P≤0.05 vs controls. Values 
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are mean ± SEM of 6–10 animals per group. *P≤0.05; **P < 0.01 and ***P < 0.001  vs 
controls.  
Page 30 of 56
For Peer Review Only
Diabetes
 Figure 1 
66x49mm (600 x 600 DPI) 
Page 31 of 56
For Peer Review Only
Diabetes
 66x49mm (600 x 600 DPI) 
Page 32 of 56
For Peer Review Only
Diabetes
 66x49mm (600 x 600 DPI) 
Page 33 of 56
For Peer Review Only
Diabetes
 66x49mm (600 x 600 DPI) 
Page 34 of 56
For Peer Review Only
Diabetes
 66x49mm (600 x 600 DPI) 
Page 35 of 56
For Peer Review Only
Diabetes
 Figure 6 
66x49mm (600 x 600 DPI) 
Page 36 of 56
For Peer Review Only
Diabetes
 Figure 7 
66x49mm (600 x 600 DPI) 
Page 37 of 56
For Peer Review Only
Diabetes
 Figure 8 
66x49mm (600 x 600 DPI) 
Page 38 of 56
For Peer Review Only
Diabetes
Figure S1
0
50
150
100
H
y
p
o
th
a
la
m
ic
 p
ro
te
in
 
le
v
e
ls
 (
a
.u
.)
 
NPY CART
H
y
p
o
th
a
la
m
ic
 p
ro
te
in
 
le
v
e
ls
 (
a
.u
.)
 
0
50
150
100
FAS ACC pACC AMPKα1 AMPKα2 pAMPK mTOR p-mTOR
A
B
MCHSaline
β-actin
FAS
ACC
pACC
AMPKα1
AMPKα2
pAMPK
mTOR
p-mTOR
Saline MCH
CART
β-actin
NPY
Page 39 of 56
For Peer Review Only
Diabetes
Figure S2
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Figure S3
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Figure S4
WAT shSIRT1
H-E
UCP-1
WAT shFOXO1
H-E
UCP-1
H-E
UCP-1
H-E
UCP-1
BAT shSIRT1
BAT shFOXO1
W
A
T
 U
C
P
-1
 p
o
s
it
iv
e
 a
re
a
  
  
  
  
  
  
  
  
  
  
(a
rb
it
ra
y
ry
 u
n
it
s
) 
0
100
150
200
250
50
GFP shSIRT1
W
A
T
 U
C
P
-1
 p
o
s
it
iv
e
 a
re
a
  
  
  
  
  
  
  
  
  
  
(a
rb
it
ra
y
ry
 u
n
it
s
) 
GFP shFoxo1
0
100
150
200
250
50
B
A
T
 U
C
P
-1
 p
o
s
it
iv
e
 a
re
a
  
  
  
  
  
  
  
  
  
  
(a
rb
it
ra
y
ry
 u
n
it
s
) 
GFP shFoxo1
0
100
150
200
50
B
A
T
 U
C
P
-1
 p
o
s
it
iv
e
 a
re
a
  
  
  
  
  
  
  
  
  
  
(a
rb
it
ra
y
ry
 u
n
it
s
) 
GFP shSIRT1
0
100
150
200
250
50
Vehicle 
MCH 
Vehicle 
MCH 
Vehicle 
MCH 
Vehicle 
MCH 
100μm100μm 100μm 100μm
100μm100μm100μm100μm
100μm 100μm 100μm 100μm
100μm 100μm 100μm 100μm
100μm 100μm 100μm 100μm
100μm 100μm 100μm 100μm
100μm100μm100μm100μm
100μm 100μm 100μm 100μm
GFP / Saline GFP / MCH shFOXO1 / Saline shFOXO1 / MCH 
GFP / Saline GFP / MCH shFOXO1 / Saline shFOXO1 / MCH 
GFP / Saline GFP / MCH shFOXO1 / Saline shFOXO1 / MCH 
GFP / Saline GFP / MCH shFOXO1 / Saline shFOXO1 / MCH 
GFP / Saline GFP / MCH shSIRT1 / Saline shSIRT1 / MCH 
GFP / Saline GFP / MCH shSIRT1 / Saline shSIRT1 / MCH 
GFP / Saline GFP / MCH shSIRT1 / Saline shSIRT1 / MCH 
GFP / Saline GFP / MCH shSIRT1 / Saline shSIRT1 / MCH 
Page 42 of 56
For Peer Review Only
Diabetes
Figure S5
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Supplementary information
Drugs
Rats received an intracerebroventricular (ICV) administration of 5 μL of vehicle or MCH 
(20 μg; Bachem, Bubendorf, Switzerland). For the inhibition of SIRT1, we used a potent 
specific inhibitor of SIRT1: Ex527 (10 μg in a total volume of 5 μL; Tocris Bioscience, 
St. Louis, MO). Mice were treated icv with MCH sense or MCH-ASO phosphorthioate-
modified oligonucleotides. MCH sense and MCH-ASO were diluted in TE buffer (10 
mM Tris–HCl, 1 mM EDTA) and injected at the beginning of the light cycle in a total 
volume of 2 μl per mouse. Phosphorthioate modified oligonucleotides for MCH (sense, 
5_-CCC TCA GTC TGG CTG-3_ and anti-sense, 5_-ACA GCC AGA CTG AGG- 3) 
were obtained from Eurofins Genomix Company (Ebersberg, Germany) (1). 
Stereotaxic microinjection of lentiviral expression vectors
 Lentiviral vectors expressing green fluorescent protein (GFP) and inhibiting SIRT1 
(shSIRT1),  FOXO1 (shFOXO1), MCHR1 (shMCHR1), POMC (shPOMC) (3,1X1006 
PFU/ml) (SIGMA-Aldrich) and GABA-R (shGABA-R) genes or scrambled sequences  
were injected bilaterally into the ARC (anterior to bregma (AP) −2.85 mm, lateral to the 
sagittal suture (L) ±0,3 mm, and ventral from the surface of the skull (V) -10,2 mm), with 
a microliter syringe (2; 3). The viral particles (1 l, 3,1X1006 PFU/ml) were infused over 
5 minutes and the injector kept in place for an additional 5 minutes. GFP fluorescence 
using a fluorescent visualized under the microscope was used as a visual marker of 
effective transduction of the lentivirus at the injection site. Dissection of the ARC was 
performed by micropunches under the microscope, as previously shown (4; 5). 
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Stereotaxic AAV-DREADD-mCherry injections
The hM3Dq coding sequences were cloned into a mCherry vector upstream of the 
mCherry sequence to generate C-terminal mCherry fusion proteins (Addgene, 
Cambridge, USA). The hM3Dq-mCherry coding sequence was amplified by PCR, and 
the amplicons and a cre-inducible AAV vector with a human Synapsin 1 promoter was 
packaged in serotype 8: 7.53X1012 PFU/ml genome copies per mL and was prepared and 
tittered at the Universidad Autonoma de Barcelona (Barcelona, Spain). ketamine-
xylazine anesthesized male AgRP-Ires-cre mice (6) were placed in a stereotaxic frame 
(David Kopf Instruments). The CRE-dependent AVV were injected bilaterally into the 
ARC of all mice (anterior to bregma (AP) −1.5 mm, lateral to the sagittal suture (L) ±0,2 
mm, and ventral from the surface of the skull (V) -6 mm) with a microliter syringe (neuros 
model 7001 KH, Hamilton, USA). The viral particles (1 l, 7.53X1009 PFU/ml) were 
infused over 10 minutes and the injector kept in place for an additional 5 minutes. 
Detection of mCherry was performed with an immunofluorescence procedure, using a 
rabbit anti-cherry (1:200; Abcam; Cambridge, UK). Detection was done with an anti-
rabbit antibody conjugated with Alexa 488 (1:200; Molecular Probes; Grand Island, NY, 
US)
Food intake experiments involving MCH-ASO or MCH-sense in AgRP-Ires-cre mice 
started after 30 min of CNO (1 mg/kg of body weight) or vehicle- i.p. injection. These 
mice were singly housed for at least 2 weeks beforehand. 
Intracerebroventricular infusions
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Rats and mice were anesthetized and cannulate to an osmotic minipump (model 2001 
Alzet Osmotic Pumps; DURECT, CA) as previously described (2; 7). The minipump was 
inserted in subcutaneous pocket on the dorsal surface. MCH was continuously infused in 
rats and mice at the following concentrations:10μg/day and 2.5μg/day respectively. The 
incision was closed with sutures, and rats were kept warm until full recovery. 
Brain slice preparation
Hypothalamic slices were cut from 8- to 12-week-old male Pomc-Cre:ROSA-tdTomato 
mice as previously described (8). Briefly, mice were anaesthetized with isoflurane, and 
after decapitation, the brain was rapidly removed and put in ice-cold oxygenated (O2 95% 
/ CO2 5%) artificial cerebrospinal fluid (ACSF) containing the following (in mM): 120 
NaCl, 3.2 KCl, 1 NaH2PO4, 26 NaHCO3, 1 MgCl2, 2 CaCl2, 2.5 glucose (osmolarity 
adjusted to 300 mOsm with sucrose, pH 7.4). After removal of the cerebellum, the brain 
was glued and coronal hypothalamic slices (250 µm thick) containing the ARC were cut 
using a vibratome (VT1200S; Leica). Before recording, slices were incubated at 35ºC for 
a recovery period of 1 h. After recovery, slices were placed in a submerged recording 
chamber (31ºC; Warner Instruments) and continuously perfused (2 ml/min) with 
oxygenated ACSF. Physiological concentration of glucose (2.5 mM) was used for 
recording (8). MCH was applied to the perfusing system (bath application) to obtain a 
final concentration of 1 µM.
Patch-clamp recordings
 ARC POMC neurons expressing the fluorophore td-Tomato were visualized with a 40x 
objective in an upright video-microscope Leica DM-LFSA equipped with fluorescence 
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and infrared differential interference contrast (IR-DIC). Whole-cell patch-clamp 
recordings were performed in current-clamp mode as previously described (8) by using a 
Multiclamp 700B amplifier (Molecular Devices). Data were filtered at 1 kHz and sampled 
at 5 kHz with Digidata 1322A interface and Clampex 10.6 from pClamp software 
(Molecular Devices). Pipettes (from borosilicate capillaries; World Precision 
Instruments) had a resistance of 6-8 MΩ when filled with an internal solution containing 
the following (in mM): 123 K-gluconate, 2 MgCl2, 8 KCl, 0.2 EGTA, 4 Na2-ATP, 0.3 
Na-GTP, and 10 HEPES, pH 7.3 with KOH. Loose patch-clamp recordings were 
performed in current-clamp mode. All recordings were analyzed with Clampfit 10.6 from 
pClamp software (Molecular Devices). Junction potential was determined to allow 
correction of membrane potential values. A series of current pulses from – 60 to 70 pA 
(1 s, 10 pA increments) was applied to measure the passive membrane properties of ARC 
POMC neurons.
Mean firing rate values were obtained before, during, and after MCH treatment. Neurons 
were considered responsive when a change of more than 20% in firing rate was observed. 
The peak response was determined, and the number of spikes was counted 2 min before 
and after the peak effect. Basal and recovery firing rate values were obtained by counting 
the number of spikes during a 4-min period before and after treatment, respectively.
Glucose tolerance test
Glucose-tolerance tests (GTT) were performed by injection of glucose (2 mg/g) 
intraperitoneally (ip) after 6 h fasting. Blood samples were collected immediately before 
and 15, 30, 60 and 120 min after glucose administration (9; 10).  
Sympathetic nerve activity (SNA) recording 
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Mice were anesthetized with ip ketamine (91 mg kg-1) and xylazine (9.1 mg kg-1). 
Anesthesia was maintained with α-chloralose (initial dose: 25mg kg-1, sustain dose: 50 
mg kg-1 h-1) via a catheter inserted in the femoral vein. The trachea was cannulated, and 
each mouse was allowed to breathe spontaneously oxygen-enriched air. Rectal 
temperature was maintained at 37.5°C using a temperature-controlled surgical table and 
a lamp. We obtained multi-fiber recording of SNA as previously described (2). Using a 
dissecting microscope, a nerve fiber innervating WAT was identified, placed on the 
bipolar platinum-iridium electrode. Each electrode was attached to a high-impedance 
probe (HIP-511, Grass Instruments) and the nerve signal was amplified 105 times with a 
Grass P5 AC pre-amplifier. After amplification, the nerve signal was filtered at a 100- 
and 1000-Hz cutoff with a nerve traffic analysis system (Model 706C, University of Iowa 
Bioengineering). The nerve signal was then routed to an oscilloscope (model 54501A, 
Hewlett-Packard) for monitoring the quality of the sympathetic nerve recording and to a 
resetting voltage integrator (model B600c, University of Iowa Bioengineering). SNA 
measurements were made every 15 min for 6 h after icv. To ensure that electrical noise 
was excluded in the assessment of sympathetic outflow, we corrected each SNA recording 
for post-mortem background activity.
Western blot analysis
Western blot were performed as previously described (2; 11-13). Hypothalami, ARC, 
MBH, WAT and liver protein lysates were homogenized in ice-cold lysis buffer 
containing 50 mmol/L Tris-HCl (pH 7.5), 1 mmol/L EGTA, 1 mmol/l EDTA, 1% Triton 
X-100, 1 mmol/l sodium orthovanadate, 50 mmol/l sodium fluoride, 5 mmol/l sodium 
pyrophosphate, 0.27 mol/l sucrose, 0.1% 2-mercaptoethanol, and complete protease and 
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phosphatase inhibitor cocktail (1 tablet/50 ml; Roche Diagnostics, Mannheim, Germany). 
Homogenates were centrifuged at 13.000g for 10 min at 4°C, supernatants were removed, 
and aliquots were snap-frozen in liquid nitrogen. Hypothalamic and ARC protein lysates 
were subjected to SDS-PAGE on 8% and 12% polyacrylamide gels and electrotransferred 
on a polyvinylidene fluoride membrane. Briefly, total protein lysates from hypothalamus 
(40 µg) or ARC (20 µg) were subjected to SDS-PAGE, electrotransferred on a 
polyvinylidene difluoride membrane. Membranes were blocked for 1 h in TBS-Tween 20 
(TBST: 50 mmol/L Tris- HCl (pH 7.5), 0.15 mol/L NaCl, and 0.1% Tween 20) containing 
5% skimmed milk or 3% BSA and probed for 16 h at 4°C in TBST, 5% skimmed milk or 
3% BSA with antibodies against ACC, phospho-ACC-Ser79 (pACC), AMPKα1 and 
AMPKα2 (Upstate); phospho-AMPK-Thr172 (pAMPK), pHSL Ser680, SAPK/JUNK 
Thr183/Tyr185, FOXO1, acetyl-p53 and p53 (Cell Signaling); AgRP (Abcam); POMC, 
NPY, CART, FAS(H-300), SIRT1, CIDE-A (N-19)R, acetyl-Foxo1, GABA-R and MCH 
pro-peptide (Santa Cruz Biotechnology), MCHR1 (Abnova) or  mTOR, p-mTOR and β-
actin (Sigma-Aldrich). Given that some processed peptides are short and are unlikely to 
be electrophoretically resolved in a blot of polyacrylamide gel we used antibodies 
detecting pre-propeptides for POMC, NPY and AgRP (for more information please see 
supplementary Table S2). Because some mature peptides are too short to be 
electrophoretically resolved in a blot of polyacrylamide gel, we used antibodies detecting 
pre-propeptides for POMC, NPY and AgRP (for more information please see 
supplementary Table S2). Membranes were then incubated with horseradish peroxidase-
conjugated secondary antibodies (Dako Denmark, Glostrup, Denmark) followed by 
chemiluminescence (Pierce ECL Western Blotting Substrate, Thermo scientific, USA). 
Then, the membranes were exposed to X-ray film (Super RX, Fuji Medical X-Ray Film, 
Fujifilm, Japan) and developed with developer and fixing liquids (AGFA, Germany) 
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under appropriate dark room conditions. Protein levels were normalized to β-actin for 
each sample. 
Real-time PCR 
Real-time PCR (TaqMan®, Applied Biosystems; Foster City, CA, USA; or SYBR® 
Green, Roche Molecular Biochemicals, Mannheim, Germany, for the hypothalamic 
nuclei samples) was performed using specific primers and probes (Table S1) as 
previously described (14). Values were expressed in relation to hypoxanthineguanine 
phosphoribosyl-transferase (HPRT) levels.
Liver TG content
The extraction procedure for liver TG was adapted from methods described previously 
(2). Livers (aprox 200 mg) were homogenized for 2 min in ice-cold chloroform-methanol 
(2:1, vol/vol). TG were extracted during 5-h shaking at room temperature. For phase 
separation, H2O MQ was added, samples were centrifuged, and the organic bottom layer 
was collected. The organic solvent was dried using a Speed Vac and dissolved in 
chloroform. TG (Randox Laboratories LTD, UK) content of each sample was measured 
in duplicate after evaporation of the organic solvent using an enzymatic method.
Hematoxylin/eosin staining and immunohistochemistry
WAT and BAT samples were fixed in 10% formalin buffer for 24 h, and then dehydrated 
and embedded in paraffin by a standard procedure. Sections of 3 μm were prepared with 
a microtome and stained using a standard Hematoxylin/Eosin Alcoholic (BioOptica) 
procedure according to the manufacturer's instructions. Alternative sections of paraffin 
were used for immunohistochemistry detection of UCP-1. Immunohistochemistry was 
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performed as previously described (15; 16) using a rabbit anti-UCP-1 (1:500 for WAT 
and 1:2000 for BAT; Abcam; Cambridge, UK). UCP-1-positive cells were counted by 
using Image J. 
Immunofluorescence 
Mice brains were fixed by perfusion followed by immersion (12 h) in 10% buffered 
formalin for 24 hours. The brain pieces were cut 50 μm thick using a Vibratome® Series 
1000. Detection of GFP, and POMC immunofluorescence; and double labelling were 
performed as previously reported (15; 17). 
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Supplementary figure legends
Supplementary Figure 1. Protein expression of some molecular markers after 
central MCH administration in the ARC. Central effects of icv MCH administration 
(20µg/rat) on, (A) hypothalamic protein levels of FAS, ACC, pACC, AMPKα1, 
AMPKα2, pAMPK, mTOR and p-mTOR and (B) hypothalamic protein levels of NPY 
and CART in rats after 2 hours. β-actin was used to normalize protein levels. Dividing 
lines indicate spliced bands from the same gel. Values are mean ± SEM of 7–10 animals 
per group. 
Supplementary Figure 2. Intracellular pathway induced by MCH in the ARC and 
specificity of the nuclei isolation. mRNA levels of FOXO1 (A), POMC (B) and AgRP 
(C) in the ARC after icv injection of MCH. VMH FOXO1 mRNA (D) and LHA (E) 
FOXO1 mRNA expression after icv MCH injection. VMH SIRT1 and FOXO1 protein 
levels (F) and LHA SIRT1 and FOXO1 protein levels (G) after the injection of MCH 
directly in the ARC. mRNA levels of POMC (H) and SF-1 (I) were measured in the ARC 
and VMH. Values are mean ± SEM of 5–8 animals per group.  *P≤0.05, **P≤0.01 and 
***P≤0.001 vs controls. 
Supplementary Figure 3. The MCH orexigenic action is blunted by the 
pharmacological blockade of SIRT1. Effects of icv injection of MCH (20µg/rat) and 
EX-527 (10µg/rat) + MCH (20µg/rat) compared to vehicle injected controls on food 
intake after 2h (A). Body weight change (B) and cummulative food intake (C) after 2 
weeks of shSIRT1 injection or GFP scrambled lentiviruses into the ARC of rats before 
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MCH administration. Values are mean ± SEM of 8–10 animals per group. *P≤0.05, 
**P≤0.01; and ***P≤0.001 vs controls. 
Supplementary Figure 4. Central MCH requires SIRT1 and FoxO1 in the 
hypothalamic ARC to induces adiposity. Representative pictures of WAT and BAT 
histology (hematoxylin-eosin) and WAT and BAT protein levels of UCP1; Values are 
mean ± SEM of 5–10 animals per group. 
Supplementary Figure 5. Central inhibition of MCH induces hypophagia. MCH 
protein levels in the different models evaluated with MCH-ASO: wild type mice (A) and 
SIRT1 Tg mice (B). Values are mean ± SEM of 5–10 animals per group. *P≤0.05, 
**P≤0.01; and ***P≤0.001 vs controls. 
Appendix figures. Uncropped blots.  
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Supplementary Table 1 related to Figure S2: Primers and probes for real-time PCR (TaqMan®) 
analysis.
mRNA Gene name Gene bank accession number Sequence of primers
AgRP Agouti-related protein NM 00360.1
FWD: 5’-CAG AGT TCT CAG GTC TAA GTC-3
REV: 5’-TTG AAG AAG CGG CAG TAG CAC-3’
Fox01 Forkhead box protein 01 NM 001191846.2 FWD: 5’-TGT GCC CTA CTT CAA GGA TAA GG-3’REV: 5’-GTG GCG AAT TGA ATT CTT CCA-3’
Hprt Hypoxanthine 
Phosphoribosyltransferase-1
NM 012583 FWD: 5’-AGC CGA CCG GTT CTG TCA T-3’REV: 5’-GGT CAT AAC CTG GTT CAT CAT CAC-3’
POMC Pro-opiomelanocortin NM 139326.2 FWD: 5’-CGT CCT CAG AGA GCT GCC TTT-3’                                                                                   REV: 5’-TGT AGC AGA ATC TCG GCA TCT TC-3’
Sf-1 Steroidogenic factor-1
Assay ID Applied Biosystems TaqMan® Gene 
Expression Assays Assay ID Rn00584298_m1
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Supplementary Table 2: List of antibodies used in the western blots and 
immunohistochemistry methods.
Protein Name of Antibody
Manufacturer, catalog and lot #, 
and/or name of individual providing 
the antibody
Species 
raised 
in
Dilution 
used Lot
ACC Anti-ACC Millipore, 04-322 rabbit 1:1000 Not available
Acetyl Foxo1 Anti-Acetyl-FKHR Santa Cruz Biotechnology, sc-101681 rabbit 1:1000 DO915
Acetyl-p53 Anti-acetyl p53 Cell Signaling, #2570 rabbit 1:500 4
AgRP Anti-AgRP propeptide Abcam, ab113481 rabbit 1:1000 GR66371-6
AMPKα1 Anti-AMPKα1 Millipore #07-350 rabbit 1:1000 2684946
AMPKα2 Anti-AMPKα2 Millipore #07-363 rabbit 1:1000 2475668
β-actin Anti-β-Actin Sigma-Aldrich A 5316 mouse 1:10000 067M4781V
CART Anti-CART (N20) Santa Cruz Biotechnology, sc-18068 GOAT 1:1000 I1911
CIDE-A Anti-CIDE-A (N-19)R Santa Cruz Biotechnology, sc-8730-R rabbit 1:1000 K1209
FAS Anti-FAS (H-300) Santa Cruz Biotechnology, sc-20140 rabbit 1:1000 G1813
FOXO1 Anti-Fox01 (C29H4) Cell Signaling, #2880 rabbit 1:1000 11
GABA-R Anti-GABA-RAP (FL-117) Santa Cruz Biotechnology  sc-28938 rabbit 1:1000 J2708
GFP Anti-GFP Abcam, ab13970 chicken 1:4000 GR3190550-14
MCH Anti-MCH pro-peptide Santa Cruz Biotechnology  sc-28931 rabbit 1:1000 B2006
MCHR1 Anti-MCH-R Abnova PAB16225 rabbit 1:1000 5487/5488AP3-1
mTOR Anti-mTOR Cell Signaling, #2972 rabbit 1:1000 10
NPY Anti-NPY propeptide Sigma-Aldrich, WH0004852 mouse 1:1000 09121-3B5
pACC Anti-phospho-ACC-Ser79 Cell Signaling, #3661 rabbit 1:1000 10
pAMPK Anti-phospho-AMPK-Thr172 Cell Signaling, 2535 rabbit 1:1000 21
pHSL Anti-phospho HSL (ser 680) Cell Signaling, 4126 rabbit 1:1000 6
pJNK Anti-SAPK/JUNK Thr183/Tyr185 Cell Signaling, #4668 rabbit 1:1000 11
p-mTOR Anti-p-mTOR (Ser 2448) Cell Signaling, #2971 rabbit 1:1000 21
POMC Anti-POMC propeptide (FL-267) Santa Cruz Biotechnology, sc-20148 rabbit 1:1000 G2810
POMC Anti-POMC  propeptide Phoenix pharmaceuticals, H029-30 rabbit 1:200 01800-4
p53 Anti-p53 (1C12) mouse mAB Cell Signalling, #2524S mouse 1:1000 13
SIRT1 Anti-SIRT1 (H-300) Santa Cruz Biotechnology, sc-15404 rabbit 1:1000 Not available
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